Literature DB >> 17917467

Evidence for two types of bipolar depression using a dimensional approach.

Chantal Henry1, Katia M'Baïlara, Rollon Poinsot, Anne-Aurelie Casteret, Frédéric Sorbara, Marion Leboyer, Eduard Vieta.   

Abstract

BACKGROUND: Although there is a great heterogeneity of depressive states in bipolar patients, there is only one definition in international classifications for describing them. However, this variety seems particularly important to recognize because of the possible exacerbation of some of these bipolar depressive states by antidepressants. We aimed at assessing whether it is possible to distinguish different forms of bipolar depression using a dimensional approach.
METHODS: We characterized 60 bipolar patients with a Major Depressive Episode (DSM-IV) using a new tool (MAThyS; Multidimensional Assessment of Thymic States), assessing five fundamental dimensions (emotional reactivity, cognitive speed, psychomotor function, motivation, and sensory perception) of mood states.
RESULTS: A cluster analysis using the items of the dimensional scale revealed two types of depressive state: group 1 (n = 38), which had a low score, is characterized by an inhibition in all dimensions, whereas group 2 (n = 22) is characterized by an overactivation. The emotional reactivity is the most relevant dimension for discriminating these two types of depression (group 1: hyporeactivity; group 2: hyperreactivity), whereas sadness is not.
CONCLUSIONS: Bipolar depressive states are not homogeneous. A dimensional approach based on emotional reactivity could be useful for discriminating the different forms of bipolar depression. Bipolar depressions may be classified as hyporeactive or hyperreactive. This classification might have therapeutic implications, because hyperreactive depression should belong to the broad spectrum of mixed states. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2007        PMID: 17917467     DOI: 10.1159/000107559

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  8 in total

Review 1.  Activated depression: mixed bipolar disorder or agitated unipolar depression?

Authors:  Alan C Swann
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

2.  Psychotherapy for Bipolar II Disorder: The Role of Interpersonal and Social Rhythm Therapy.

Authors:  Holly A Swartz; Jessica C Levenson; Ellen Frank
Journal:  Prof Psychol Res Pr       Date:  2012-04

Review 3.  Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder.

Authors:  Andrea Fagiolini; Anna Coluccia; Giuseppe Maina; Rocco N Forgione; Arianna Goracci; Alessandro Cuomo; Allan H Young
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 4.  Bipolar disorder diagnosis: challenges and future directions.

Authors:  Mary L Phillips; David J Kupfer
Journal:  Lancet       Date:  2013-05-11       Impact factor: 79.321

Review 5.  Emotional dysfunction as a marker of bipolar disorders.

Authors:  Chantal Henry; Mary Phillips; Ellen Leibenluft; Katia M'Bailara; Josselin Houenou; Marion Leboyer
Journal:  Front Biosci (Elite Ed)       Date:  2012-06-01

6.  Improvement in Fatigue, Sleepiness, and Health-Related Quality of Life with Bright Light Treatment in Persons with Seasonal Affective Disorder and Subsyndromal SAD.

Authors:  Cecilia Rastad; Jan Ulfberg; Per Lindberg
Journal:  Depress Res Treat       Date:  2011-06-13

7.  Construction and validation of a dimensional scale exploring mood disorders: MAThyS (Multidimensional Assessment of Thymic States).

Authors:  Chantal Henry; Katia M'Bailara; Flavie Mathieu; Rollon Poinsot; Bruno Falissard
Journal:  BMC Psychiatry       Date:  2008-09-19       Impact factor: 3.630

8.  Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS).

Authors:  Chantal Henry; Amandine Luquiens; Christophe Lançon; Hélène Sapin; Marcel Zins-Ritter; Stephanie Gerard; Elena Perrin; Bruno Falissard; Michael Lukasiewicz
Journal:  BMC Psychiatry       Date:  2013-03-13       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.